Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis as well as extra-muscular organ complications including interstitial lung disease (ILD). Over the last 25 years, a wealth of clinical, epidemiological, genetic, and experimental data have collectively supported a role for Jo-1 in mediating deleterious cell-mediated, adaptive immune responses contributing to the disease phenotype of the anti-synthetase syndrome. Complementing these studies, more recent work suggests that unique, non-enzymatic functional properties of Jo-1 also endow this antigen with the capacity to activate components of the innate immune system, particularly cell surface as well as endosomal Toll-like receptors and their downstream signaling pathways. Combining these facets of Jo-1-mediated immunity now supports a more integrated model of disease pathogenesis that should lead to improved therapeutic targeting in the anti-synthetase syndrome and related subsets of idiopathic inflammatory myopathy.

Original languageEnglish (US)
Article number56
JournalCurrent Rheumatology Reports
Volume17
Issue number9
DOIs
StatePublished - Sep 27 2015

Fingerprint

Ligases
Myositis
Histidine-tRNA Ligase
Toll-Like Receptors
Interstitial Lung Diseases
Adaptive Immunity
Autoantibodies
Immune System
Immunity
Phenotype
Antigens
Therapeutics

Keywords

  • Adaptive immunity
  • Anti-synthetase syndrome
  • Autoantibody
  • Histidyl-tRNA synthetase (HRS = Jo-1)
  • Innate immunity
  • Toll-like receptor (TLR)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome. / Ascherman, Dana.

In: Current Rheumatology Reports, Vol. 17, No. 9, 56, 27.09.2015.

Research output: Contribution to journalArticle

@article{af07b21a75444d43a06b2af5a8a03ee2,
title = "Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome",
abstract = "Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis as well as extra-muscular organ complications including interstitial lung disease (ILD). Over the last 25 years, a wealth of clinical, epidemiological, genetic, and experimental data have collectively supported a role for Jo-1 in mediating deleterious cell-mediated, adaptive immune responses contributing to the disease phenotype of the anti-synthetase syndrome. Complementing these studies, more recent work suggests that unique, non-enzymatic functional properties of Jo-1 also endow this antigen with the capacity to activate components of the innate immune system, particularly cell surface as well as endosomal Toll-like receptors and their downstream signaling pathways. Combining these facets of Jo-1-mediated immunity now supports a more integrated model of disease pathogenesis that should lead to improved therapeutic targeting in the anti-synthetase syndrome and related subsets of idiopathic inflammatory myopathy.",
keywords = "Adaptive immunity, Anti-synthetase syndrome, Autoantibody, Histidyl-tRNA synthetase (HRS = Jo-1), Innate immunity, Toll-like receptor (TLR)",
author = "Dana Ascherman",
year = "2015",
month = "9",
day = "27",
doi = "10.1007/s11926-015-0532-1",
language = "English (US)",
volume = "17",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome

AU - Ascherman, Dana

PY - 2015/9/27

Y1 - 2015/9/27

N2 - Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis as well as extra-muscular organ complications including interstitial lung disease (ILD). Over the last 25 years, a wealth of clinical, epidemiological, genetic, and experimental data have collectively supported a role for Jo-1 in mediating deleterious cell-mediated, adaptive immune responses contributing to the disease phenotype of the anti-synthetase syndrome. Complementing these studies, more recent work suggests that unique, non-enzymatic functional properties of Jo-1 also endow this antigen with the capacity to activate components of the innate immune system, particularly cell surface as well as endosomal Toll-like receptors and their downstream signaling pathways. Combining these facets of Jo-1-mediated immunity now supports a more integrated model of disease pathogenesis that should lead to improved therapeutic targeting in the anti-synthetase syndrome and related subsets of idiopathic inflammatory myopathy.

AB - Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis as well as extra-muscular organ complications including interstitial lung disease (ILD). Over the last 25 years, a wealth of clinical, epidemiological, genetic, and experimental data have collectively supported a role for Jo-1 in mediating deleterious cell-mediated, adaptive immune responses contributing to the disease phenotype of the anti-synthetase syndrome. Complementing these studies, more recent work suggests that unique, non-enzymatic functional properties of Jo-1 also endow this antigen with the capacity to activate components of the innate immune system, particularly cell surface as well as endosomal Toll-like receptors and their downstream signaling pathways. Combining these facets of Jo-1-mediated immunity now supports a more integrated model of disease pathogenesis that should lead to improved therapeutic targeting in the anti-synthetase syndrome and related subsets of idiopathic inflammatory myopathy.

KW - Adaptive immunity

KW - Anti-synthetase syndrome

KW - Autoantibody

KW - Histidyl-tRNA synthetase (HRS = Jo-1)

KW - Innate immunity

KW - Toll-like receptor (TLR)

UR - http://www.scopus.com/inward/record.url?scp=84938903210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938903210&partnerID=8YFLogxK

U2 - 10.1007/s11926-015-0532-1

DO - 10.1007/s11926-015-0532-1

M3 - Article

VL - 17

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 9

M1 - 56

ER -